Clinically, combining PD-1/PD-L1 blockade with strategies that neutralize or reprogram CAF subtypes and their exosomes, such as miRNA inhibitors, metabolic modulators, or engineered exosomes, may overcome immune exclusion and enhance immunotherapy durability in HNSCC. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.